N. Mingngamsup

A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteers

P. Opanasopit, P. Saelao, C. Sawangmake, 2022, medRxiv.

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

K. Srisutthisamphan, K. Chokephaibulkit, P. Licciardi, 2022, Human vaccines & immunotherapeutics.

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.

K. Srisutthisamphan, K. Chokephaibulkit, P. Licciardi, 2022, medRxiv.

Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers

Songsak Tongchusak, T. Pisitkun, P. Opanasopit, 2023, Scientific reports.